SLNO
Soleno Therapeutics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
SLNO Profile
Soleno Therapeutics, Inc.
A clinical-stage biopharmaceutical company that currently developing a once-daily oral tablet for the treatment of Prader-Willi syndrome
Life Science Tools and Services
08/25/1999
11/13/2014
NASDAQ Stock Exchange
92
12-31
Common stock
203 Redwood Shores Parkway, Suite 500, Redwood City, California 94065
--
Soleno Therapeutics, Inc., was incorporated in Delaware on August 25, 1999. The company focuses on the development and commercialization of novel therapies for the treatment of rare diseases. The company's lead drug candidate, DCCR (diazachol) sustained-release tablets, is a potent ATP-sensitive potassium (KATP) channel activator.